newsfilter
← Latest News
PR Newswire·

Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026

  • Tyra Biosciences, Inc. (Nasdaq: TYRA) will host a conference call & webcast on September 9, 2026, at 8:00 am ET.
  • The event will discuss initial clinical results from the SURF302 Phase 2 study of oral dabogratinib for intermediate risk non-muscle invasive bladder cancer (IR NMIBC).
  • Participants can access the live webcast & slide presentation on the "For Investors" page of the TYRA website or register via a provided link for telephone dial-in.
  • A replay of the call & webcast will be archived on the company's website for at least 90 days.
  • Tyra Biosciences is a Carlsbad, California-based clinical-stage biotechnology company focused on FGFR biology & utilizes its SNÅP platform for drug design.
  • Lead candidate dabogratinib is a potential first-in-class selective FGFR3 inhibitor being developed for LG-UTUC, IR NMIBC, & ACH.
  • Additional pipeline assets include TYRA-430 for advanced hepatocellular carcinoma (SURF431 study) & TYRA-200 for metastatic intrahepatic cholangiocarcinoma (SURF201 study).